Androgen deprivation therapy associated with increased risk for fatal heart attack
the ONA take:
Androgen deprivation therapy (ADT) and radiation therapy (RT) prolong survival in men with unfavorable-risk prostate cancer; however, evidence suggests that ADT is associated with nonfatal cardiovascular events.
Specifically, long-term follow-up of a randomized clinical trial that compared ADT and RT with RT alone showed that men with significant comorbidity, most commonly prior heart attack, who received ADT died earlier. These findings are published in a research letter in the Journal of the American Medical Association.
In this study, overall survival and death due to prostate cancer, fatal heart attack, and all other causes were analyzed. The study included 206 men with unfavorable-risk prostate cancer who were randomized to receive RT alone or RT and 6 months of ADT. The men were also categorized into subgroups based on prior comorbidity, including prior heart attack.
The findings demonstrate that prior heart attack is associated with an increased risk of fatal heart in men who receive ADT for unfavorable-risk prostate cancer.
Evidence suggests that androgen deprivation therapy is associated with nonfatal cardiovascular events.
- More Than Half of Melanomas Are Self-Detected, Especially by Women
- Childhood Cancer Linked to Poor Diet Quality in Adult Survivors
- New Research Identifies Potential Bladder Cancer Chemotherapy Side Effect
- POLST Programs Can Benefit from the Relationship Between Patients and Nurse Practitioners
- Olaratumab in Combo With Doxorubicin Approved for Soft Tissue Sarcoma
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Implementing a Distress Screening Process for Cancer Patients
- Initiating Palliative Care in the Emergency Department
- Exercise is as Effective in Treating Metastatic Prostate Cancer as Medication
- Adherence to Tamoxifen, AIs Among Older Women is Low, Study Shows
- Replacing Neoadjuvant CRT with Multiagent Chemo Not Recommended for Rectal Cancer
- Study Identifies Factors Associated With Infection-related Complications in ALL
- Immune Checkpoint-Related Neurotoxicity May Be More Common During Combination Treatment
- New Recommendations for Secondary Prevention of Cervical Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|